Physician profile
Jonathan D Baumgard
NPI 1730178146
$356.47
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $92.66.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $186.99 | 2019-2020 | |
| Sanofi Pasteur INC. | $58.09 | 2019-2020 | |
| Cranial Technologies, INC | $31.09 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $26.34 | 2019 | |
| Ironshore Pharmaceuticals INC. | $25.43 | 2020 | |
| Glaxosmithkline, LLC. | $17.57 | 2019 | |
| Tris Pharma INC | $10.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Baumgard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.